2025 San Antonio Breast Cancer Symposium (SABCS)
(December 9-12th, 2024 in San Antonio, TX)
Molecular causes of subtype switching in primary and metastatic breast tumor pairs from the AURORA US Project
Anna R. Michmerhuizen, Brooke M. Felsheim, Gregory L. Wheeler, Benjamin J. Kelly, Manali Singha, Toshinori Hinoue, William C. Nenad, Ana C. Garrido-Castro, Justin Balko, Karthik Giridhar, Uma Chandran, Adrian Lee, Lisa A. Carey, Tari A. King, Katherine A. Hoadley, Peter W. Laird, Elaine R. Mardis, Charles M. Perou, and the AURORA US Metastasis Network
Poster Spotlight 2: 7:00-8:30am CST in 301 ABC
Poster Discussion: PD2-06
Molecular characterization of resistance to antibody drug conjugates in metastatic breast cancer: a prospective analysis from the AURORA US Network
Ana C. Garrido-Castro, William C. Nenad, Justin M. Balko, Toshinori Hinoue, Gregory L. Wheeler, Benjamin J. Kelly, Manali Singha, Brooke M. Felsheim, Anna R. Michmerhuizen, Uma Chandran, Adrian V. Lee, Lisa A. Carey, Tari A. King, Elaine Mardis, Peter W. Laird, Karthik V. Giridhar, Katherine A. Hoadley, Charles M. Perou, and the AURORA US Metastasis Network
Poster Spotlight 3: 7:00-8:30am CST in 302 ABC
Poster Discussion: PD3-09
Characterizing circulating tumor cell (CTC) enumeration and phenotypic profiling in blood with synchronously obtained tissue in metastatic breast cancer (MBC) in TBCRC / Aurora US
Karthik V. Giridhar, Will Nenad, Hong Ye, Gregory Wheeler, Toshinori Hinoue, Uma Chandran, Ben Kelly, Elaine Mardis, Peter Laird, Justin Balko, Ana Garrido-Castro, Rita Nanda, Nancy Lin, Carey Anders, Claudine Isaacs, Jessie Tao, Jesus Anampa, Nusrat Jahan, Laura Huppert, Angie DiMchele, Ben Park, Shaveta Vinayak, Amy Delson, Mark Magbanua, Marija Balik, Heather Parsons, Adrian Lee, Lisa Carey, Larry Norton, Antonio Wolff, Nancy Davidson, Ian Krop, Tari King, Chuck Perou, Aurora US Network, Katie Hoadley
Poster Session 2: 5:00-6:30pm CST in the Exhibit Hall
Poster: PS2-07-17
Peripheral Immune Profiling During Neoadjuvant HER2-Targeted Therapy in HER2-Positive (HER2+) Early Breast Cancer (EBC): Mass Cytometry (CyTOF) Analysis from the MARGOT Trial (TBCRC 052)
Elia Segui, Hillary Heiling, Joanna Baginska, Allison N. Nau, Ilana Gomez Diaz, Julia Huezo, Paula R. Pohlmann, Mothaffar F. Rimawi, Natalie F. Sinclair, Rachel L. Yung, Nancy U. Lin, Antonio C. Wolff, Michelle K. DeMeo, Ashley Root, Tasnim Rahman, Ayesha Mohammed-Abreu, Molly DiLullo, Ashka Patel, Esther R. Ogayo, Tari A. King, Eric P. Winer, Elizabeth A. Mittendorf, Nabihah Tayob, Sara M. Tolaney, Ian E. Krop, Judith Agudo, Adrienne G. Waks
Poster Session 2: 5:00-6:30pm CST in the Exhibit Hall
Poster: PS2-08-10
Immune biomarkers of standard-of-care chemoimmunotherapy response and resistance in real-world patient population: TBCRC 061
Justin M. Balko, Paula I. Gonzalez-Ericsson, Brandie Taylor, Andres Ocampo, Joseph Serrenho, Susan Opalenik, Violeta Sanchez, Melinda Sanders, Mothaffar Rimawi, Yara Abdou, Sara Nunnery, Rita Nanda, Frederick Howard, Jesus Anampa-Mesia, Laura Kennedy
Poster Session 2: 5:00-6:30pm CST in the Exhibit Hall
Poster: PS2-07-15
Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer
Ho, AY; Gharibpoor, FP; Abdou, Y; Anampa, J, Blitzblau, R; Calhoun, B; Dent, D; Daugherty. K; Fox, J; Garber, H; Hwang ES; Khan, A; Leone, P; Mutter, R; Patil, S; Santa-Maria, C; Vincent, B; Wright, JL; Spring, L; Gupta, G
General Session 2: 9:00am-12:00pm CST in Hall 1
Oral Presentation: GS2-05
QuantifyHER (Trial In Progress): Quantitative Immunofluorescence and/or Messenger RNA to Measure HER2 Expression in Patients With Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan (TBCRC 066)
Eleanor P. Taranto, Fawn White, Desirae Chandran, Emma Walinsky, Shannon Deluca, Lauren Bayne, Paul Wileyto, Anupama Shirali, Charles J. Robbins, Yara Abdou, Jesus Anampa-Mesia, Marija Balic, Jenna V. Canzoniero, Nan C. Chen, Frederick Howard, Laura Huppert, Adriana Kahn, Candace Mainor, Jason Mouabbi, Vidhya Nair, Traci DeGeer, Jodi Weidler, Thomas McNicholas, Christine Serway, Joachim Reischl, M. Bates, Robert Monroe, David L. Rimm, Angela DeMichele
Poster Session 4: 5:00-6:30pm CST in the Exhibit Hall
Poster: PS4-03-12
TBCRC 056: A phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the TNBC cohort
Erica L. Mayer, Noah Graham, Roberto A. Leon-Ferre, Mariya Rozenblit, Cesar A. Santa-Maria, Steven Isakoff, Jennifer Specht, Nadine Tung, Vandana Abramson, Jennifer Desrosiers, Alexander Schubert, Beyza Koca, Sara M. Tolaney, Eric P. Winer, Ian E. Krop, Antonio C. Wolff, Geoffrey I. Shapiro, Nabihah Tayob, Jennifer L. Guerriero
Rapid Fire 5: 12:30-1:30pm CST in Stars at Night 1-2
Oral Presentation: RF5-02
TBCRC 058: A randomized phase 2 study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
Rita Nanda, Yuan Chen, Yara Abdou, Nusrat Jahan, Erica L. Mayer, Michelle Melisko, Ange Syldor, Chaya Friedman, Jennifer Savoie, Fresia Pareja, Britta Weigelt, Sarat Chandarlapaty, Nicholas Turner, Marina Sharifi, Suzanne Conzen, Tiffany Traina
Poster Session 5: 12:30-2:00pm CST in the Exhibit Hall
Poster: PS5-09-04
ESMO Congress 2025
(October 17th-21st, 2025 in Berlin, Germany)
Randomized Window Trial Comparing Molecular Impact of SERD vs AI vs Tamoxifen in ILC (TBCRC 037)
Oesterreich S, Zhou J, Shi X, Wang S, Sikora MJ, Clark BZ, Holt M, Hieken T, Mukhtar RA, Linden H, Nangia J, Gallagher K, Stringer-Reasor E, Bedrosian I, Feldman S, Nanda R, Bolsvert M, Rothman J, Thorpe H, Atkinson JM, Tatsuoka C, Davidson NE, Thompson A, Tseng G, Adrian V Lee, Jankowitz RC, McAuliffe PF
Poster
2025 American Society of Clinical Oncology (ASCO)
(May 30th – June 3rd, 2025 in Chicago, IL)
Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial)
Natasha Hunter, Heather Parsons, Leslie Cope, Jenna Canzoniero, Rita Denbow, Fabio Navarro, Sherif El-Refai, Sean Boyle, Jesus Anampa, Mothaffar Rimawi, Angela Pennisi, Anna Maria Storniolo, Candace Mainor, Rita Nanda, Angela DeMichele, Gaorav Gupta, Erica Stringer-Reasor, Vered Stearns, Antonio Wolff, Ben Park
Rapid Oral Abstract Session: The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by BCRF: ctDNA for Breast Cancer: It’s Here- Are We Ready?; 4:30-6pm CT, Arie Crown Theater
Oral Presentation Time: 4:42pm CT
Abstract: 1009
Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in INFORM (TBCRC 031) patients with low stromal TILs
Stuart Schnitt, Nadine Tung, Judy Garber, Satabhisa Mukhopadhyay, Tathagata Dasgupta, Craig Bunnell
Poster Session: Breast Cancer- Local/ Regional/ Adjuvant; Hall A; 9am-12pm CT
Poster Board: 204
Abstract: 611
Phase 1 trial of exercise as first-line therapy for hormone receptor (HR)–positive advanced breast cancer (TBCRC 054)
Neil Iyengar, Jessica Lavery, Adele Carlson, Vanessa Castillo, Sarah Lehman, Meghan Michalski, Jenna Harrison, Alexis Braun, Jessica Flores, Su Chun, Catherine Lee, Jesus Anampa, Tarah Ballinger, Jennifer Sheng, Chaya Moskowitz, Lee Jones
Poster Session: Breast Cancer- Metastatic; Hall A; 9am-12pm CT
Poster Board: 67
Abstract: 1088
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
Tiffany Traina, Yuan Chen, Katia Khoury, Hope Rugo, Erica Mayer, Yara Abdou, Michelle Melisko, Fresia Pareja, Britta Weigelt, Sarat Chandarlapaty, Nicholas Turner, Joshua Lang, Marina Sharifi, Suzanne Conzen, Rita Nanda
Poster Session: Breast Cancer- Metastatic; Hall A; 9am-12pm CT
Poster Board: 110a
Abstract: TPS1142
ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negative Metastatic BREast Cancer (MBC) (TBCRC-067)
Laura Huppert, Leif Ellisen, Carey Anders, Claudine Isaacs, Cesar Santa-Maria, Jesus Anampa, Angela DeMichele, Marija Balic, Jennifer Specht, Maryam Lustberg, Antonio Wolff, Ian Krop, Hope Rugo
Poster Session: Breast Cancer- Metastatic; Hall A; 9am-12pm CT
Poster Board: 107b
Abstract: TPS1137
2025 Publications
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
Maeve A. Hennessy, Ashley Cimino-Mathews, Jodi M. Carter, Jennifer M. Kachergus, Yaohua Ma, Jeffrey P. Leal, Lilja B. Solnes, Vandana G. Abramson, Lisa A. Carey, Mothaffar Rimawi, Jennifer Specht, Anna Maria Storniolo, Christos Vaklavas, Ian Krop, Eric Winer, Rita Denbow, Vincente Valero, Antonio C. Wolff, Richard L. Wahl, Chiung-Yu Huang, Vered Stearns, E. Aubrey Thompson, Roisin M. Connolly
Breast, 2025 Jun; PMID: 40049115
Prognostic Value of Visually and Computationally-Assessed Tumor-Infiltrating Lymphocytes in Early-Stage Triple-Negative Breast Cancer (TBCRC-030)
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, Vandana G Abramson, Adam Brufsky, Erica Michelle Stringer-Reasor, Susan Faye Dent, Tiffany A. Traina, Lisa A. Carey, Mothaffar F. Rimawi, Jennifer M. Specht, Kathy Miller, Cesar Augusto Santa-Maria, Tathagata Dasgupta, Busem Binboğa Kurt, Ian E. Krop, Nadine M. Tung, Stuart J. Schnitt, Nabihah Tayob, Erica L. Mayer
J Natl Cancer Inst., 2025 Oct 11; PMID: 41075163
System-Level Transformations to Increase Patient Participation in Clinical Trials (TBCRC 057)
Nicole E. Caston; Luqin Deng; Courtney P. Williams; Emily B. Levitan; Andres Azuero; Russell Griffin; Karen L. Smith; Antonio C. Wolff; Michelle E. Melisko; Eileen H. Shinn; Kathleen Gallagher; Rebekah Angove; Stephanie B. Wheeler; Gabrielle B. Rocque
JCO Oncol Pract., 2025 Mar 13; PMID: 40080789